AI assistant
AYTU BIOPHARMA, INC — Director's Dealing 2021
May 11, 2021
35030_dirs_2021-05-10_5e6a2bbc-6a41-46c8-a287-10e26d6d504b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AYTU BIOPHARMA, INC (AYTU)
CIK: 0001385818
Period of Report: 2021-03-20
Reporting Person: ARMISTICE CAPITAL, LLC (Director)
Reporting Person: Armistice Capital Master Fund Ltd. (Director)
Reporting Person: Boyd Steven (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-20 | Common Stock | J | 6959 | — | Acquired | 1340293 | Direct |
| 2021-03-20 | Common Stock | J | 0 | — | Acquired | 1340293 | Indirect |
| 2021-03-29 | Common Stock | J | 2085 | — | Acquired | 1342378 | Direct |
| 2021-03-29 | Common Stock | J | 0 | — | Acquired | 1342378 | Indirect |
Footnotes
F1: The reported shares of common stock (the "Shares") of Aytu BioPharma, Inc. (the "Issuer") are directly held by Armistice s (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
F2: The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the "CVRs") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc ("Innovus") upon consummation of the merger between the Issuer and Innovus on February 14, 2020. The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones.